By Guest Columnist Dr. Stephanie Duguid Our most recent speaker through the Mississippi Health Ambassador Initiative was Dr.

Alzheimer’s disease doesn’t have a cure, meaning no treatment can reverse the damage that’s already occurred in the brain.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

In August, NICE declined to recommend Biogen and Eisai’s Leqembi (lecanemab) for reimbursement. Three months later, NICE followed with the same decision on Lilly’s Kisunla (donanemab).

Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab). Lecanemab was authorised by the MHRA for ...

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant ...

Her husband isn't sure if it made a difference. In 2020 ... That sort of uncertainty is common when it comes to Leqembi and Kisunla, two new Alzheimer's drugs approved since 2023.

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

For Eisai and Biogen, the CHMP’s decision to stick by its previous call now punts the final approval verdict for Leqembi back to the European Commission (EC), which is the ultimate authority on ...

Lantheus has recognized the immense opportunity in Alzheimer’s disease following the approval of Leqembi and Kisunla and the development of many other β-amyloid and Tau tangle therapies.